CORRIGENDUM***Stem and progenitor cell-mediated tumor selective gene therapy***

KS Aboody, J Najbauer and MK Danks

Gene Therapy (2008) 15, 1072; doi:10.1038/gt.2008.106

Correction to: Gene Therapy (2008) 15, 739–752;
doi:10.1038/gt.2008.41

Since the publication of the above paper the authors have requested changes to be made on page 745, a new reference has also been listed.

Page 7, right column

‘While a minimal-to-no immunogenic potential is certainly possible since, for example, the HB1.F3 cell line used in our laboratories expresses undetectable levels of MHC Class I antigens and extremely low levels of Class II antigens, the more likely probability is that reported by Aboody *et al.*³ These investigators showed that stem/progenitor cells of neural origin elicit a subacute, limited, local immune response characterized by detectable T-cell infiltration, but with persistence of viable HB1.F3 human NSCs in syngeneic models of immunocompetent mice bearing syngeneic orthotopic gliomas.’

This should read as:

‘While a minimal-to-no immunogenic potential is certainly possible since, for example, the HB1.F3 cell line used in our laboratories expresses detectable levels of MHC Class I antigens and extremely low levels of Class II antigens.¹³⁶ Recent data suggest that stem/progenitor cells of neural origin elicit a subacute, limited, local immune response characterized by detectable T-cell infiltration, but with persistence of viable HB1.F3 human NSCs in syngeneic models of immunocompetent mice bearing syngeneic orthotopic gliomas (KS Aboody *et al.*, *unpublished observations*).’

The following citation should be indicated at the end of References.

136. Lee EM, Kim JY, Cho BR, Chung WK, Yoon BW, Kim SU *et al.* Down-regulation of MHC class I expression in human neuronal stem cells using viral stealth mechanism. *Biochem Biophys Res Commun* 2005; **326**: 825–835.